Cramer Says Celera (CRA) Could Be Next Pharma Takeover Target

Playing to the recent trend toward consolidation within the pharma sector, Cramer touted Celera (NYSE: CRA) as a potential takeover target on Friday's Mad Money. He believes none other than Abbott Labs (NYSE: ABT) could be the possible aquiree, as the two companies are already partners.

Cramer believes the two would fit nicely together as many of Celera's products focus on personalized treatments which require "frequent monitoring and reassessment."

Sending a cautionary message, however, Cramer warns that Celera should only be viewed as a speculative play. Jim points out that Celera currently trades at 41x earnings, and could report earnings growth of 50% this year.

Shares of Celera are currently up 6.5%, most recently trading at $9.14. The stock is likely seeing upside today on the back of Pfizer's (NYSE: PFE) announcement that it intends to acquire Wyeth (NYSE: WYE) for about $50.19 per share.

You May Also Be Interested In

• Bitwise declares monthly distributions for six crypto option ETFs
• Faraday Future receives U.S. patent for hybrid transmission system
• Jade Biosciences names Mark Eisner to its board of directors